EUVIMEDOpdag EUVIMED
Crossref

Identification of a novel ALDH1A3‐selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity‐based drug target discovery

Hiroshi Kamiyama, Masayuki Miyano, Daisuke Ito, Takayuki Kimura, Koji Hagiwara, Hiroyuki Kogai, Yosuke Kaburagi, Yoshihiko Kotake, Yasutaka Takase

Chemical Biology & Drug Design · 2023-03 · 101 (3) · 727-739

DOI: 10.1111/cbdd.14176 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2022-11-25. Written by Hiroshi Kamiyama and 8 co-authors. Institution: Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan. Major MEDLINE topics: Aldehyde Oxidoreductases, Phosphodiesterase Inhibitors. Cited 8 times so far (Crossref); 57 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The identification of biologically active target compounds and their binding proteins is important in mechanism‐of‐action studies for drug development. Additionally, the newly discovered binding proteins provide unforeseen ideas for novel drug discovery and for subsequent structural transformation to improve target specificity. Based on the lead and final candidate compounds related to the type 5 phosphodiesterase (PDE5) inhibitor E4021, we designed chemical probes and identified their target proteins by the affinity chromatography approach. Aldehyde dehydrogenase family 1 member A3 (ALDH1A3), currently reported as a cancer stem cell target, was clearly isolated as a binding protein of the lead ‘immature’ inhibitor probe against PDE5. In the early derivatization to the closely related structure, Compound 5 (ER‐001135935) was found to significantly inhibit ALDH1A3 activity. The discovery process of a novel ALDH1A3‐selective inhibitor with affinity‐based binder identification is described, and the impact of this identification method on novel drug discovery is discussed.

Subjects

MeSH terms (MEDLINE)

Aldehyde OxidoreductasesPhosphodiesterase InhibitorsNeoplastic Stem CellsDrug Discovery

Author keywords

ALDH1A3-selective inhibitorPDE5affinity chromatographychemical probedrug target discovery

Substances

Aldehyde OxidoreductasesPhosphodiesterase Inhibitors

Authors and institutions

  • Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.

Cite

APA

Kamiyama, H., Miyano, M., Ito, D., Kimura, T., Hagiwara, K., Kogai, H., Kaburagi, Y., Kotake, Y., & Takase, Y. (2023). Identification of a novel ALDH1A3‐selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity‐based drug target discovery. Chemical Biology & Drug Design, 101(3), 727-739. https://doi.org/10.1111/cbdd.14176

Vancouver

Kamiyama H, Miyano M, Ito D, Kimura T, Hagiwara K, Kogai H, et al. Identification of a novel ALDH1A3‐selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity‐based drug target discovery. Chemical Biology & Drug Design. 2023;101(3):727-739. doi:10.1111/cbdd.14176

BibTeX
@article{Kamiyama2023,
  author = {Kamiyama, Hiroshi and Miyano, Masayuki and Ito, Daisuke and Kimura, Takayuki and Hagiwara, Koji and Kogai, Hiroyuki and Kaburagi, Yosuke and Kotake, Yoshihiko and Takase, Yasutaka},
  title = {Identification of a novel ALDH1A3‐selective inhibitor by a chemical probe with unrelated bioactivity: An approach to affinity‐based drug target discovery},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  volume = {101},
  number = {3},
  pages = {727--739},
  doi = {10.1111/cbdd.14176}
}
Start for free →